Pediatric and YA trials of CD19-directed CAR T-cell therapy
| Reference . | T-cell engager . | Population . | CR/MRD− CR . | Persistence EFS/OS . |
|---|---|---|---|---|
| 8 (single center) | CD19 scFv/4-1BB CD3ζ | 25 pediatric/YA patients (age 5-22 y) | 90%/82% (infused patients) | 6-mo EFS, 67% (infused)/OS, 78% (infused) |
| 5 adult patients (age 26-60 y) | 3 patients BMT in CR, 1 patient DLI due to MRD | |||
| 15 | CD19 scFv/ CD28 CD3ζ | 21 pediatric/YA patients (age 5-27 y) | 70%/60% (all enrolled patients) | 9.7-mo OS, 52% |
| LFS of 12 patients achieving MRD− was 78.8%; intent was BMT; 10/12 MRD− proceeded to BMT; 2 ineligible for BMT relapsed | ||||
| 16 | CD19 scFv/4-1BB CD3ζ | 45 pediatric/YA patients (age 1-25 y) | 89% (all enrolled), 93% (infused); all patients with MRD− CR | 1-y EFS, 50.8% (infused)/OS, 65.9% (infused) |
| 11 patients received BMT | ||||
| 9 (ELIANA multicenter trial) | CD19 scFv/4-1BB CD3ζ | 92 enrolled, 75 infused pediatric/YA patients (age 3-23 y) | 66% (all enrolled) | 1-y EFS, 50% (infused)/OS, 76% (infused) |
| 81% (infused); all CRs required 2 time points 4 wk apart and were MRD− | 8 patients BMT (6 in MRD− remission, 2 with MRD+ disease) |
| Reference . | T-cell engager . | Population . | CR/MRD− CR . | Persistence EFS/OS . |
|---|---|---|---|---|
| 8 (single center) | CD19 scFv/4-1BB CD3ζ | 25 pediatric/YA patients (age 5-22 y) | 90%/82% (infused patients) | 6-mo EFS, 67% (infused)/OS, 78% (infused) |
| 5 adult patients (age 26-60 y) | 3 patients BMT in CR, 1 patient DLI due to MRD | |||
| 15 | CD19 scFv/ CD28 CD3ζ | 21 pediatric/YA patients (age 5-27 y) | 70%/60% (all enrolled patients) | 9.7-mo OS, 52% |
| LFS of 12 patients achieving MRD− was 78.8%; intent was BMT; 10/12 MRD− proceeded to BMT; 2 ineligible for BMT relapsed | ||||
| 16 | CD19 scFv/4-1BB CD3ζ | 45 pediatric/YA patients (age 1-25 y) | 89% (all enrolled), 93% (infused); all patients with MRD− CR | 1-y EFS, 50.8% (infused)/OS, 65.9% (infused) |
| 11 patients received BMT | ||||
| 9 (ELIANA multicenter trial) | CD19 scFv/4-1BB CD3ζ | 92 enrolled, 75 infused pediatric/YA patients (age 3-23 y) | 66% (all enrolled) | 1-y EFS, 50% (infused)/OS, 76% (infused) |
| 81% (infused); all CRs required 2 time points 4 wk apart and were MRD− | 8 patients BMT (6 in MRD− remission, 2 with MRD+ disease) |
BMT, bone marrow transplantation; CR, complete remission; LFS, leukemia-free survival; OS, overall survival; YA, young adult.